基础医学与临床2026，Vol.46Issue(1)：39-45,7.DOI:10.16352/j.issn.1001-6325.2026.01.0039
小檗碱增强前列腺癌细胞系22RV1对多西他赛的化疗敏感性
Berberine enhances the chemotherapy sensitivity of prostate cancer cell line 22RV1 to docetaxel
摘要
Abstract
Objective To investigate the chemotherapy effectiveness of berberine(BBR)to enhance sensitivity of prostate cancer cell line 22RV1 to docetaxel.Methods The docetaxel(DTX)resistant cell was constructed using prostate cancer cell line 22RV1.The drug-resistant cell strain(22RV1/DTX)was divided into:22RV1/DTX group,low concentration(L)-BBB+22RV1/DTX group,high concentration(H)-BBB+22RV1/DTX group and H-BBR+ERK activator+22RV1/DTX group.CCK8 method was applied to detect cell proliferation.Scratch healing test was applied to detect migration.Transwell test was applied to detect invasion.Flow cytometry was applied to de-tect apoptosis.Western blot was applied to detect the expression of extra-cellular regulated protein kinases(ERK),pERK,and ETS transcription factor(ELK1)proteins in cells.Results Compared with 22RV1/DTX group,the proliferation,migration,and invasion of cells in the L-BBR+22RV1/DTX group and H-BBR+22RV1/DTX group were lower but the apoptosis rate was higher(P＜0.05).The proliferation,migration,and invasion of cells in the H-BBR+ERK activator+22RV1/DTX group were higher,and the apoptosis rate was lower(P＜0.05).BBR signifi-cantly reduced the pERK/ERK ratio and ELK1 protein expression level in 22RV1/DTX cells(P＜0.05).The effects on 22RV1/DTX cells and pathways were reversed by ERK activator(P＜0.05).Conclusions BBR may inhibit the proliferation,migration,and invasion of drug-resistant cells,promote cell apoptosis and thus enhance the chemo-therapy sensitivity of prostate cancer cells to DTX with underlying mechanism of suppressing the ERK/ELK1 signa-ling pathway.关键词
小檗碱/ERK/ELK1/前列腺癌细胞/化疗敏感性Key words
berberine/ERK/ELK1/prostate cancer cell/chemotherapy sensitivity分类
医药卫生引用本文复制引用
陆巍,王焱旻,刘炳辰,陶欣,王世鹏,曹秋也..小檗碱增强前列腺癌细胞系22RV1对多西他赛的化疗敏感性[J].基础医学与临床,2026,46(1):39-45,7.基金项目
吉林省卫生健康科技能力提升项目(2021JC055) （2021JC055）
